Zhenoluten®
RESEARCH METHODS
The patients’ complaints were assessed in progression, a general clinical examination of blood and
urine, a biochemical study of blood on the REFLOTRON apparatus (Boehringer Mannheim, Germany)
were carried out. Ultrasound examination of the ovaries was performed using an ultrasound machine
(ALOKA, Japan). The content of hormones (FSH, LH, and estradiol) in the blood serum was determined
by radioimmunoassay. The radioactivity of the samples was counted on a «Tracor Analytic 1285»
counter (USA-Holland).
RESEARCH RESULTS
It was found that the use of ZHENOLUTEN® in patients with mild and moderate climacteric syndrome
contributed to an improvement in the general condition, which was manifested in a decrease in the
number of hot flashes, improved sleep, appetite, and increased efficiency (Table 1).
Dynamics of subjective indicators in patients with climacteric Table 1
syndrome.
Indicator Number of Patients. %
Before Treatment After Treatment with Conventional After Treatment with
Methods (Control Group) ZHENOLUTEN® (Primary
Group)
Hot flushes in the head and 72,0 55,1* 31,8*#
upper body.
Increased sweating. 67,8 50,7* 29,6*#
Fast fatiguability. 68,8 51,3* 31,4*#
Reduced performance. 81,6 53,1* 32,6*#
Irritability. 91,8 54,2* 33,3*#
*p <0.05 compared with the indicator in patients before treatment;
# p <0.05 compared with the indicator in patients after treatment with conventional methods.
In laboratory studies, after the application of ZHENOLUTEN®, a significant decrease in the content of
FSH and LH was noted, which caused an increase in the LH / FSH index to the lower limits of age-re-
lated physiological fluctuations (Table 2).
The noted changes in the hormonal status of patients while taking ZHENOLUTEN® correlate with
clinical indicators. They indicate the restoration of the adequate adaptive response of the aging or-
ganism in response to an age-related decrease in ovarian function.
Effect of ZHENOLUTEN®on the content of pituitary hormones in blood serum Table 2
of patients with climacteric syndrome.
Indicator Norm Before Treatment After Treatment with After Treatment with
Conventional Drugs (Control ZHENOLUTEN®
Group) (Primary Group)
FSH, (IU / ml) 1,5-45 89,3±3,5 71,6±6,3* 46,8±3,9*#
LH, (IU / ml) 2-17 28,1±1,9 25,7±2,4 16,4±1,4*#
* p <0.05 - statistically significant compared with the indicator before treatment.
# p <0.05 - statistically significant in comparison with the indicator in patients of the control group.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.